CAR T-Cells and Safety Signals

This episode considers a new treatment for hypertrophic cardiomyopathy, the world’s most common inherited heart condition, which most affected people don’t even realize they have. A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400702. 

In the face of a growing childhood obesity epidemic, some parents and clinicians are turning to new tools such as GLP-1 receptor agonists. This episode explores the implications of that trend. A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp240070 ...  Show more

<span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;">Drs. John Sweetenham and Fred Locke discuss the FDA investigation on the risk of cancer from CAR T-cell therapy and share insights on the known number of cases and the potential implic ...

CAR T cells are genetically engineered to express a receptor that recognizes and kills tumor cells. CAR T-cell products are now FDA approved for 6 hematologic malignancies. Author Jennifer N. Brudno, MD, National Cancer Institute, joins JAMA Deputy Editor Mary McGrae McDermott ...

In this week’s episode, we pause from our discussion about DLBCL to talk about the fundamentals of CAR-T, BiTE and autologous transplants, which will lay the foundation for subsequent discussions about DLBCL. These therapies are the talk ...

In this episode, Dr. Hind Rafei dives into the cutting-edge world of CAR-NK cell therapy and its potential to revolutionize cancer treatment. Unlike their T-cell counterparts, CAR-NK cells promise enhanced safety and innate tumor-killing ability. But what if their power could ...